Group 1 - The core viewpoint of the news is that HuaLing Pharmaceutical has successfully completed the first dosing of its second-generation glucose kinase activator (GKA) HMS1005 in a Phase Ib multiple ascending dose (MAD) trial in the United States, marking a significant step in expanding its presence in the overseas diabetes market [1][2] - HMS1005 is designed as a novel molecular entity with improved physicochemical properties, featuring a sustained-release formulation that allows for once-daily dosing, enhancing patient convenience and potentially improving adherence to treatment [1] - The successful completion of the Phase Ib clinical trial will lead the company to seek partnerships for the global market development of HMS1005, further solidifying its leading position in the global GKA sector [1] Group 2 - The CEO of HuaLing Pharmaceutical, Dr. Chen Li, emphasized that the initiation of the Phase Ib clinical trial in the U.S. is a critical step in leading the innovation of diabetes drug development and overseas market expansion [2] - The company aims to validate the safety and tolerability of the second-generation GKA through robust trial design and strong R&D execution, laying a solid foundation for future clinical development [2] - HuaLing Pharmaceutical is committed to exploring better treatment options while deepening its existing product market, with plans to continue advancing more innovative drugs and global outreach to provide new treatment hopes for patients with type 2 diabetes [2]
华领医药(02552)在美国启动第二代GKA的Ⅰb期临床试验并完成首例受试者入组